{"title":"无肾患者肾移植前后的维生素 D 代谢物","authors":"","doi":"10.1053/j.ajkd.2024.03.025","DOIUrl":null,"url":null,"abstract":"<div><h3>Rationale & Objective</h3><div>Kidneys are vital for vitamin D<span><span> metabolism, and disruptions in both production and catabolism occur in chronic kidney disease. Although </span>vitamin D<span><span> activation occurs in numerous tissues, the kidneys are the most relevant source of circulating active vitamin D. This study investigates extrarenal vitamin D activation and the impact of kidney transplantation on </span>vitamin D metabolism in patients who are anephric.</span></span></div></div><div><h3>Study Design</h3><div>Case series.</div></div><div><h3>Setting & Participants</h3><div><span>Adult patients with previous bilateral nephrectomy (anephric) not receiving active vitamin D therapy evaluated at the time of (N</span> <!-->=<!--> <!-->38) and 1 year after (n<!--> <!-->=<!--> <!-->25) kidney transplantation.</div></div><div><h3>Analytical Approach</h3><div><span><span>Chromatography with tandem mass spectrometry was used to measure vitamin D metabolites. Activity of </span>CYP24A1 [24,25(OH)</span><sub>2</sub>D/25(OH)D] and CYP27B1 [1α,25(OH)<sub>2</sub>D/25(OH)D] is expressed as metabolic ratios. Differences between time points were evaluated by paired <em>t</em>-test or Wilcoxon matched-pairs signed-rank test.</div></div><div><h3>Results</h3><div>At time of transplantation, 1α,25(OH)<sub>2</sub>D was detectable in all patients (4-36<!--> <!-->pg/mL). There was a linear relationship between 25(OH)D and 1α,25(OH)<sub>2</sub>D levels (r<!--> <em>=</em> <!-->0.58, P<!--> <!--><<!--> <!-->0.001), with 25(OH)D explaining 34% of the variation in 1α,25(OH)<sub>2</sub>D levels. There were no associations between 1α,25(OH)<sub>2</sub><span><span>D and biointact parathyroid hormone (PTH) or </span>fibroblast growth factor 23 (FGF-23). One year after transplantation, 1α,25(OH)</span><sub>2</sub>D levels recovered (+205%), and CYP27B1 activity increased (+352%). Measures of vitamin D catabolism, 24,25(OH)<sub>2</sub><span>D and CYP24A1 activity increased 3- to 5-fold. Also, at 12 months after transplantation, 1α,25(OH)</span><sub>2</sub>D was positively correlated with PTH (ρ<!--> <!-->=<!--> <!-->0.603, <em>P</em> <!-->=<!--> <!-->0.04) but not with levels of 25(OH)D or FGF-23.</div></div><div><h3>Limitations</h3><div>Retrospective, observational study design with a small cohort size.</div></div><div><h3>Conclusions</h3><div>Low-normal levels of 1α,25(OH)<sub>2</sub>D was demonstrated in anephric patients, indicating production outside the kidneys. This extrarenal CYP27B1 activity may be more substrate driven than hormonally regulated. Kidney transplantation seems to restore kidney CYP27B1 and CYP24A1 activity, as evaluated by vitamin D metabolic ratios, resulting in both increased vitamin D production and catabolism. These findings may have implications for vitamin D supplementation strategies in the setting of kidney failure and transplantation.</div></div><div><h3>Plain-Language Summary</h3><div>Vitamin D activation occurs in multiple tissues, but the kidneys are considered the only relevant source of circulating levels. This study investigates vitamin D activation outside the kidneys by measuring vitamin D metabolites in 38 patients without kidneys. Active vitamin D was detectable in all patients, indicating production outside of the kidneys. There was a strong relationship between active and precursor vitamin D levels, but no association with mineral metabolism hormones, indicating that vitamin D production was more substrate dependent than hormonally regulated. One year after kidney transplantation, active vitamin D levels increased 2-fold and breakdown products increased 3-fold, indicating that production and degradation of the hormone recovers after kidney transplantation. These findings are relevant for future research into vitamin D supplementation in kidney failure.</div></div>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":null,"pages":null},"PeriodicalIF":9.4000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Vitamin D Metabolites Before and After Kidney Transplantation in Patients Who Are Anephric\",\"authors\":\"\",\"doi\":\"10.1053/j.ajkd.2024.03.025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Rationale & Objective</h3><div>Kidneys are vital for vitamin D<span><span> metabolism, and disruptions in both production and catabolism occur in chronic kidney disease. Although </span>vitamin D<span><span> activation occurs in numerous tissues, the kidneys are the most relevant source of circulating active vitamin D. This study investigates extrarenal vitamin D activation and the impact of kidney transplantation on </span>vitamin D metabolism in patients who are anephric.</span></span></div></div><div><h3>Study Design</h3><div>Case series.</div></div><div><h3>Setting & Participants</h3><div><span>Adult patients with previous bilateral nephrectomy (anephric) not receiving active vitamin D therapy evaluated at the time of (N</span> <!-->=<!--> <!-->38) and 1 year after (n<!--> <!-->=<!--> <!-->25) kidney transplantation.</div></div><div><h3>Analytical Approach</h3><div><span><span>Chromatography with tandem mass spectrometry was used to measure vitamin D metabolites. Activity of </span>CYP24A1 [24,25(OH)</span><sub>2</sub>D/25(OH)D] and CYP27B1 [1α,25(OH)<sub>2</sub>D/25(OH)D] is expressed as metabolic ratios. Differences between time points were evaluated by paired <em>t</em>-test or Wilcoxon matched-pairs signed-rank test.</div></div><div><h3>Results</h3><div>At time of transplantation, 1α,25(OH)<sub>2</sub>D was detectable in all patients (4-36<!--> <!-->pg/mL). There was a linear relationship between 25(OH)D and 1α,25(OH)<sub>2</sub>D levels (r<!--> <em>=</em> <!-->0.58, P<!--> <!--><<!--> <!-->0.001), with 25(OH)D explaining 34% of the variation in 1α,25(OH)<sub>2</sub>D levels. There were no associations between 1α,25(OH)<sub>2</sub><span><span>D and biointact parathyroid hormone (PTH) or </span>fibroblast growth factor 23 (FGF-23). One year after transplantation, 1α,25(OH)</span><sub>2</sub>D levels recovered (+205%), and CYP27B1 activity increased (+352%). Measures of vitamin D catabolism, 24,25(OH)<sub>2</sub><span>D and CYP24A1 activity increased 3- to 5-fold. Also, at 12 months after transplantation, 1α,25(OH)</span><sub>2</sub>D was positively correlated with PTH (ρ<!--> <!-->=<!--> <!-->0.603, <em>P</em> <!-->=<!--> <!-->0.04) but not with levels of 25(OH)D or FGF-23.</div></div><div><h3>Limitations</h3><div>Retrospective, observational study design with a small cohort size.</div></div><div><h3>Conclusions</h3><div>Low-normal levels of 1α,25(OH)<sub>2</sub>D was demonstrated in anephric patients, indicating production outside the kidneys. This extrarenal CYP27B1 activity may be more substrate driven than hormonally regulated. Kidney transplantation seems to restore kidney CYP27B1 and CYP24A1 activity, as evaluated by vitamin D metabolic ratios, resulting in both increased vitamin D production and catabolism. These findings may have implications for vitamin D supplementation strategies in the setting of kidney failure and transplantation.</div></div><div><h3>Plain-Language Summary</h3><div>Vitamin D activation occurs in multiple tissues, but the kidneys are considered the only relevant source of circulating levels. This study investigates vitamin D activation outside the kidneys by measuring vitamin D metabolites in 38 patients without kidneys. Active vitamin D was detectable in all patients, indicating production outside of the kidneys. There was a strong relationship between active and precursor vitamin D levels, but no association with mineral metabolism hormones, indicating that vitamin D production was more substrate dependent than hormonally regulated. One year after kidney transplantation, active vitamin D levels increased 2-fold and breakdown products increased 3-fold, indicating that production and degradation of the hormone recovers after kidney transplantation. These findings are relevant for future research into vitamin D supplementation in kidney failure.</div></div>\",\"PeriodicalId\":7419,\"journal\":{\"name\":\"American Journal of Kidney Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":9.4000,\"publicationDate\":\"2024-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Kidney Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0272638624007820\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Kidney Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0272638624007820","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
肾脏对维生素 D 的代谢至关重要,慢性肾脏病会导致维生素 D 的生成和分解紊乱。虽然维生素 D 的活化发生在许多组织中,但肾脏是循环活性维生素 D 的最相关来源。本研究调查了肾外维生素 D 的活化以及肾移植对无肾患者维生素 D 代谢的影响。分析方法采用串联质谱色谱法测量维生素 D 代谢物。CYP24A1[24,25(OH)2D/25(OH)D]和CYP27B1[1α,25(OH)2D/25(OH)D]的活性以代谢比率表示。时间点之间的差异通过配对 t 检验或 Wilcoxon 配对符号秩检验进行评估。结果所有患者在移植时均可检测到 1α,25(OH)2D(4-36 pg/mL)。25(OH)D 与 1α、25(OH)2D 水平之间存在线性关系(r = 0.58,P < 0.001),25(OH)D 可解释 34% 的 1α、25(OH)2D 水平变化。1α,25(OH)2D与生物接触甲状旁腺激素(PTH)或成纤维细胞生长因子23(FGF-23)之间没有关联。移植一年后,1α,25(OH)2D水平恢复(+205%),CYP27B1活性增加(+352%)。维生素 D 分解代谢、24,25(OH)2D 和 CYP24A1 活性增加了 3 至 5 倍。此外,在移植后 12 个月,1α,25(OH)2D 与 PTH 呈正相关(ρ = 0.603,P = 0.04),但与 25(OH)D 或 FGF-23 的水平无关。这种肾外 CYP27B1 活性可能更多地由底物驱动,而非激素调节。根据维生素 D 代谢比率评估,肾移植似乎能恢复肾脏 CYP27B1 和 CYP24A1 的活性,从而增加维生素 D 的产生和分解。这些发现可能会对肾衰竭和移植背景下的维生素 D 补充策略产生影响。本研究通过测量 38 名无肾脏患者体内的维生素 D 代谢物,研究了肾脏以外的维生素 D 激活情况。所有患者都能检测到活性维生素 D,这表明维生素 D 是在肾脏之外产生的。活性维生素 D 水平与前体维生素 D 水平之间存在密切关系,但与矿物质代谢激素没有关系,这表明维生素 D 的产生更多取决于底物而非激素调节。肾移植一年后,活性维生素D水平增加了2倍,分解产物增加了3倍,这表明激素的产生和降解在肾移植后会恢复。这些发现对今后研究肾衰竭患者补充维生素D具有重要意义。
Vitamin D Metabolites Before and After Kidney Transplantation in Patients Who Are Anephric
Rationale & Objective
Kidneys are vital for vitamin D metabolism, and disruptions in both production and catabolism occur in chronic kidney disease. Although vitamin D activation occurs in numerous tissues, the kidneys are the most relevant source of circulating active vitamin D. This study investigates extrarenal vitamin D activation and the impact of kidney transplantation on vitamin D metabolism in patients who are anephric.
Study Design
Case series.
Setting & Participants
Adult patients with previous bilateral nephrectomy (anephric) not receiving active vitamin D therapy evaluated at the time of (N = 38) and 1 year after (n = 25) kidney transplantation.
Analytical Approach
Chromatography with tandem mass spectrometry was used to measure vitamin D metabolites. Activity of CYP24A1 [24,25(OH)2D/25(OH)D] and CYP27B1 [1α,25(OH)2D/25(OH)D] is expressed as metabolic ratios. Differences between time points were evaluated by paired t-test or Wilcoxon matched-pairs signed-rank test.
Results
At time of transplantation, 1α,25(OH)2D was detectable in all patients (4-36 pg/mL). There was a linear relationship between 25(OH)D and 1α,25(OH)2D levels (r = 0.58, P < 0.001), with 25(OH)D explaining 34% of the variation in 1α,25(OH)2D levels. There were no associations between 1α,25(OH)2D and biointact parathyroid hormone (PTH) or fibroblast growth factor 23 (FGF-23). One year after transplantation, 1α,25(OH)2D levels recovered (+205%), and CYP27B1 activity increased (+352%). Measures of vitamin D catabolism, 24,25(OH)2D and CYP24A1 activity increased 3- to 5-fold. Also, at 12 months after transplantation, 1α,25(OH)2D was positively correlated with PTH (ρ = 0.603, P = 0.04) but not with levels of 25(OH)D or FGF-23.
Limitations
Retrospective, observational study design with a small cohort size.
Conclusions
Low-normal levels of 1α,25(OH)2D was demonstrated in anephric patients, indicating production outside the kidneys. This extrarenal CYP27B1 activity may be more substrate driven than hormonally regulated. Kidney transplantation seems to restore kidney CYP27B1 and CYP24A1 activity, as evaluated by vitamin D metabolic ratios, resulting in both increased vitamin D production and catabolism. These findings may have implications for vitamin D supplementation strategies in the setting of kidney failure and transplantation.
Plain-Language Summary
Vitamin D activation occurs in multiple tissues, but the kidneys are considered the only relevant source of circulating levels. This study investigates vitamin D activation outside the kidneys by measuring vitamin D metabolites in 38 patients without kidneys. Active vitamin D was detectable in all patients, indicating production outside of the kidneys. There was a strong relationship between active and precursor vitamin D levels, but no association with mineral metabolism hormones, indicating that vitamin D production was more substrate dependent than hormonally regulated. One year after kidney transplantation, active vitamin D levels increased 2-fold and breakdown products increased 3-fold, indicating that production and degradation of the hormone recovers after kidney transplantation. These findings are relevant for future research into vitamin D supplementation in kidney failure.
期刊介绍:
The American Journal of Kidney Diseases (AJKD), the National Kidney Foundation's official journal, is globally recognized for its leadership in clinical nephrology content. Monthly, AJKD publishes original investigations on kidney diseases, hypertension, dialysis therapies, and kidney transplantation. Rigorous peer-review, statistical scrutiny, and a structured format characterize the publication process. Each issue includes case reports unveiling new diseases and potential therapeutic strategies.